Literature DB >> 14558887

The heptapeptide LSARLAF mediates platelet activation through phospholipase Cgamma2 independently of glycoprotein IIb-IIIa.

Andrew C Pearce1, Peter Wonerow, Stuart J Marshall, Jon Frampton, T Kent Gartner, Steve P Watson.   

Abstract

The seven-amino-acid peptide LSARLAF has been reported to activate platelets via the integrin GPIIb-IIIa (glycoprotein IIb-IIIa). Activation by LSARLAF is reinforced by release of ADP and thromboxanes, but the initiating event in the signalling cascade is not known. In the present study, we demonstrate that LSARLAF stimulates Src kinase-dependent tyrosine phosphorylation of many of the proteins in the GPIIb-IIIa cascade, including the tyrosine kinase Syk, the adapter SLP-76 (SH2-containing leucocyte phosphoprotein of 76 kDa) and PLCgamma2 (phospholipase Cgamma2). A critical role for PLCgamma2 in signalling by LSARLAF was demonstrated by abolition of aggregation in PLCgamma2-/- murine platelets to low concentrations of the peptide, although a partial recovery was seen with higher concentrations. In sharp contrast with the GPIIb-IIIa-regulated signalling cascade, aggregation was inhibited in murine platelets deficient in the adapter LAT (linker for activation of T-cells) and the Fc receptor gamma-chain. Aggregation was also partially inhibited by the cholesterol-lowering reagent, beta-methyl-cyclodextrin, at concentrations that disrupt membrane rafts, but do not interfere with signalling by GPIIb-IIIa. Furthermore, LSARLAF also stimulated tyrosine phosphorylation in GPIIb-deficient murine platelets, confirming that the integrin is not critical for activation of intracellular signalling pathways. LSARLAF also stimulated Ca2+ elevation in RBL-2H3 cells, which lack the platelet glycoproteins GPIIb, GPVI and GPIb. These results demonstrate that LSARLAF activates platelets through a PLCgamma2-dependent pathway that lies downstream of Src kinases and which is partially dependent on the Fc receptor gamma-chain, LAT and lipid rafts. The mechanism of cell activation by LSARLAF remains to be established, although the present results indicate that more than one surface glycoprotein may mediate this response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14558887      PMCID: PMC1223919          DOI: 10.1042/BJ20031298

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  37 in total

Review 1.  Signaling through platelet integrin alpha IIb beta 3: inside-out, outside-in, and sideways.

Authors:  S J Shattil
Journal:  Thromb Haemost       Date:  1999-08       Impact factor: 5.249

2.  The molecular adapter SLP-76 relays signals from platelet integrin alphaIIbbeta3 to the actin cytoskeleton.

Authors:  A Obergfell; B A Judd; M A del Pozo; M A Schwartz; G A Koretzky; S J Shattil
Journal:  J Biol Chem       Date:  2000-12-11       Impact factor: 5.157

3.  Rhodocytin induces platelet aggregation by interacting with glycoprotein Ia/IIa (GPIa/IIa, Integrin alpha 2beta 1). Involvement of GPIa/IIa-associated src and protein tyrosine phosphorylation.

Authors:  K Suzuki-Inoue; Y Ozaki; M Kainoh; Y Shin; Y Wu; Y Yatomi; T Ohmori; T Tanaka; K Satoh; T Morita
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

Review 4.  The integrin alpha IIb/beta 3 in human platelet signal transduction.

Authors:  B Payrastre; K Missy; C Trumel; S Bodin; M Plantavid; H Chap
Journal:  Biochem Pharmacol       Date:  2000-10-15       Impact factor: 5.858

5.  Phospholipase Cgamma2 is essential in the functions of B cell and several Fc receptors.

Authors:  D Wang; J Feng; R Wen; J C Marine; M Y Sangster; E Parganas; A Hoffmeyer; C W Jackson; J L Cleveland; P J Murray; J N Ihle
Journal:  Immunity       Date:  2000-07       Impact factor: 31.745

6.  Rhodocytin (aggretin) activates platelets lacking alpha(2)beta(1) integrin, glycoprotein VI, and the ligand-binding domain of glycoprotein Ibalpha.

Authors:  W Bergmeier; D Bouvard; J A Eble; R Mokhtari-Nejad; V Schulte; H Zirngibl; C Brakebusch; R Fässler; B Nieswandt
Journal:  J Biol Chem       Date:  2001-05-14       Impact factor: 5.157

7.  Interaction of fibrinogen with its platelet receptor. Differential effects of alpha and gamma chain fibrinogen peptides on the glycoprotein IIb-IIIa complex.

Authors:  J S Bennett; S J Shattil; J W Power; T K Gartner
Journal:  J Biol Chem       Date:  1988-09-15       Impact factor: 5.157

8.  A collagen-related peptide regulates phospholipase Cgamma2 via phosphatidylinositol 3-kinase in human platelets.

Authors:  J M Pasquet; R Bobe; B Gross; M P Gratacap; M G Tomlinson; B Payrastre; S P Watson
Journal:  Biochem J       Date:  1999-08-15       Impact factor: 3.857

Review 9.  Beta3 tyrosine phosphorylation in alphaIIbbeta3 (platelet membrane GP IIb-IIIa) outside-in integrin signaling.

Authors:  D R Phillips; L Nannizzi-Alaimo; K S Prasad
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

10.  Fyn and Lyn phosphorylate the Fc receptor gamma chain downstream of glycoprotein VI in murine platelets, and Lyn regulates a novel feedback pathway.

Authors:  L S Quek; J M Pasquet; I Hers; R Cornall; G Knight; M Barnes; M L Hibbs; A R Dunn; C A Lowell; S P Watson
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

View more
  3 in total

1.  Vav family proteins are required for optimal regulation of PLCgamma2 by integrin alphaIIbbeta3.

Authors:  Andrew C Pearce; Owen J T McCarty; Simon D J Calaminus; Elena Vigorito; Martin Turner; Steve P Watson
Journal:  Biochem J       Date:  2007-02-01       Impact factor: 3.857

2.  Peptide LSARLAF induces integrin β3 dependent outside-in signaling in platelets.

Authors:  Haixia Niu; Zhenlu Xu; Ding Li; Lin Zhang; Kemin Wang; Donald B Taylor; Junling Liu; T Kent Gartner
Journal:  Thromb Res       Date:  2012-04-05       Impact factor: 3.944

3.  Inhibition of αIIbβ3 Ligand Binding by an αIIb Peptide that Clasps the Hybrid Domain to the βI Domain of β3.

Authors:  Wen Hwa Lee; Elisabeth Schaffner-Reckinger; Demokritos C Tsoukatos; Kelly Aylward; Vassilios Moussis; Vassilios Tsikaris; Paraskevi Trypou; Marion Egot; Dominique Baruch; Nelly Kieffer; Christilla Bachelot-Loza
Journal:  PLoS One       Date:  2015-09-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.